Abstract: The present invention relates to novel therapeutic compounds, known as RNAi agents, that decrease expression of the ANGPTL8 receptor (expressed by the ANGPTL8 gene), thereby decreasing expression of mRNA and protein expression. Such RNAi agents are useful in the treatment of diseases involving the regulation of ANGPTL8 expression and function, such as dyslipidemia, a cardiovascular disorder, or a cardiometabolic disorder.
| # | Name | Date |
|---|---|---|
| 1 | 202517069638-STATEMENT OF UNDERTAKING (FORM 3) [22-07-2025(online)].pdf | 2025-07-22 |
| 3 | 202517069638-Sequence Listing in PDF [22-07-2025(online)].pdf | 2025-07-22 |
| 4 | 202517069638-REQUEST FOR EXAMINATION (FORM-18) [22-07-2025(online)].pdf | 2025-07-22 |
| 5 | 202517069638-POWER OF AUTHORITY [22-07-2025(online)].pdf | 2025-07-22 |
| 6 | 202517069638-NOTIFICATION OF INT. APPLN. NO. & FILING DATE (PCT-RO-105-PCT Pamphlet) [22-07-2025(online)].pdf | 2025-07-22 |
| 7 | 202517069638-FORM 18 [22-07-2025(online)].pdf | 2025-07-22 |
| 8 | 202517069638-FORM 1 [22-07-2025(online)].pdf | 2025-07-22 |
| 9 | 202517069638-DECLARATION OF INVENTORSHIP (FORM 5) [22-07-2025(online)].pdf | 2025-07-22 |
| 10 | 202517069638-COMPLETE SPECIFICATION [22-07-2025(online)].pdf | 2025-07-22 |
| 11 | 202517069638-CLAIMS UNDER RULE 1 (PROVISIO) OF RULE 20 [22-07-2025(online)].pdf | 2025-07-22 |